JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

Chromobacterium violaceum bacteremia: a case report.

Chromobacterium violaceum is confined in tropical and subtropical regions, which can cause life-threatening disease. It is the only Chromobacterium species that is pathogenic to humans. Because of its rarity, clinicians often do not appreciate its importance when it is isolated. We report a fulminate fatal case of C. violaceum bacteremia in a 20-year-old male Taiwanese. The clinical manifestations were fever and abdominal pain, followed by shock and pulmonary septic embolism. Emergent laparotomy identified acute appendicitis with rupture. Flomoxef sodium was administered immediately. However, his condition deteriorated rapidly and he died within 48 h after the onset of illness. Two sets of blood culture yielded C. violaceum. Physicians should be aware of the occurrence of this infection in summer season.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app